MATRix (HD-Methotrexate + HD-Cytarabine + Thiotepa + Rituximab), 4 cycles
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | None declared |
|---|
| ID | REG-MATRIX |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
STUB. IELSG32 trial standard induction. autoSCT BCNU+thiotepa consolidation is a separate phase, not part of this regimen. Hydration + urine alkalinization mandatory for HD-MTX.
Used By
Contraindications
CI-RENAL-FAILURE-FOR-HD-MTX- CI-RENAL-FAILURE-FOR-HD-MTX
Indication
IND-PCNSL-1L-MATRIX- IND-PCNSL-1L-MATRIX